Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 142.58
(-2.03%)
INR 142.58
(-2.03%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 106.6 Million INR | -15.53% |
| 2022 | 126.2 Million INR | 417.87% |
| 2021 | 24.36 Million INR | -97.91% |
| 2020 | 1.16 Billion INR | 1729.88% |
| 2019 | 63.78 Million INR | 484.9% |
| 2018 | 10.9 Million INR | -33.33% |
| 2017 | 16.35 Million INR | -25.0% |
| 2016 | 21.8 Million INR | -20.0% |
| 2015 | 27.26 Million INR | -16.67% |
| 2014 | 32.71 Million INR | -14.28% |
| 2013 | 38.16 Million INR | -12.5% |
| 2012 | 43.61 Million INR | -24.04% |
| 2011 | 57.42 Million INR | -8.86% |
| 2010 | 63 Million INR | 195.77% |
| 2009 | 21.3 Million INR | 23.94% |
| 2008 | 17.18 Million INR | 0.0% |
| 2007 | - INR | 0.0% |
| 2006 | - INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - INR | 0.0% |
| 2024 Q1 | - INR | 0.0% |
| 2023 Q2 | 110.8 Million INR | 0.0% |
| 2023 Q4 | 106.6 Million INR | 0.0% |
| 2023 FY | 106.6 Million INR | -15.53% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 126.2 Million INR | 417.87% |
| 2022 Q4 | 126.2 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 76.9 Million INR | 0.0% |
| 2021 Q2 | 408.5 Million INR | 0.0% |
| 2021 Q4 | 24.36 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 24.36 Million INR | -97.91% |
| 2020 FY | 1.16 Billion INR | 1729.88% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 50.4 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 1.16 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 63.78 Million INR | 0.0% |
| 2019 FY | 63.78 Million INR | 484.9% |
| 2019 Q2 | 71.1 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 10.9 Million INR | 0.0% |
| 2018 Q2 | 10.9 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 10.9 Million INR | -33.33% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 16.35 Million INR | -25.0% |
| 2017 Q4 | 16.35 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 16.4 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 21.8 Million INR | 0.0% |
| 2016 FY | 21.8 Million INR | -20.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 21.8 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 27.26 Million INR | -16.67% |
| 2015 Q2 | 27.3 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 27.26 Million INR | 0.0% |
| 2014 Q4 | 32.71 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 32.71 Million INR | -14.28% |
| 2014 Q2 | 32.7 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 38.2 Million INR | 0.0% |
| 2013 Q4 | 38.16 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 38.16 Million INR | -12.5% |
| 2012 Q4 | 43.61 Million INR | 0.0% |
| 2012 FY | 43.61 Million INR | -24.04% |
| 2011 FY | 57.42 Million INR | -8.86% |
| 2011 Q4 | 57.42 Million INR | 0.0% |
| 2010 FY | 63 Million INR | 195.77% |
| 2009 FY | 21.3 Million INR | 23.94% |
| 2008 FY | 17.18 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2006 FY | - INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | 83.047% |
| Bafna Pharmaceuticals Limited | 107.53 Million INR | 0.867% |
| FDC Limited | 2.46 Million INR | -4222.79% |
| Gufic Biosciences Limited | 1.53 Billion INR | 93.076% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 99.663% |
| Nectar Lifesciences Limited | 1.4 Billion INR | 92.402% |
| Orchid Pharma Limited | 1.2 Billion INR | 91.148% |
| Alkem Laboratories Limited | 400 Million INR | 73.35% |
| Bajaj HealthCare Limited | 650.34 Million INR | 83.609% |
| Brooks Laboratories Limited | 3.56 Million INR | -2890.182% |
| Eris Lifesciences Limited | 6.54 Billion INR | 98.371% |
| Glenmark Life Sciences Limited | 147.61 Million INR | 27.783% |
| Solara Active Pharma Sciences Limited | 1.17 Billion INR | 90.923% |
| Innova Captab Limited | 2.1 Billion INR | 94.936% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -41.061% |
| Wanbury Limited | 820 Million INR | 87.0% |
| Lupin Limited | 1.55 Billion INR | 93.135% |
| Aarti Drugs Limited | 2.75 Billion INR | 96.128% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -26550.0% |
| Albert David Limited | 6.01 Million INR | -1671.941% |
| Alembic Limited | 73.9 Million INR | -44.249% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Hester Biosciences Limited | 1.81 Billion INR | 94.136% |
| Hikal Limited | 4.22 Billion INR | 97.479% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | 4.503% |
| Ind-Swift Limited | 10.09 Billion INR | 98.944% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Lincoln Pharmaceuticals Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | 20.174% |
| Medico Remedies Limited | 8.67 Million INR | -1129.244% |
| Morepen Laboratories Limited | 33.64 Million INR | -216.885% |
| Procter & Gamble Health Limited | 68.8 Million INR | -54.942% |
| RPG Life Sciences Limited | -30.3 Million INR | 451.815% |
| Sigachi Industries Limited | 265.79 Million INR | 59.894% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -701.504% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | 49.801% |
| Themis Medicare Limited | 267.74 Million INR | 60.185% |
| Unichem Laboratories Limited | 382.22 Million INR | 72.11% |
| Vaishali Pharma Limited | 35.98 Million INR | -196.251% |
| Venus Remedies Limited | 386.8 Million INR | 72.441% |
| Windlas Biotech Limited | 20.18 Million INR | -428.246% |
| ZIM Laboratories Limited | 356 Million INR | 70.057% |
| Sakar Healthcare Limited | 549.55 Million INR | 80.602% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 99.501% |
| Divi's Laboratories Limited | 20 Million INR | -433.0% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -282.957% |
| Mankind Pharma Limited | 325.81 Million INR | 67.282% |
| Sequent Scientific Limited | 1.42 Billion INR | 92.531% |
| Laurus Labs Limited | 7.98 Billion INR | 98.665% |
| Neuland Laboratories Limited | 449.2 Million INR | 76.269% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | 54.907% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | 92.973% |
| Zydus Lifesciences Limited | 251 Million INR | 57.53% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -663.173% |
| Wockhardt Limited | 8.91 Billion INR | 98.804% |
| Bal Pharma Limited | 363.82 Million INR | 70.7% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | 98.22% |
| Bliss GVS Pharma Limited | 355.92 Million INR | 70.05% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 9.2 Million INR | -1058.696% |
| Shilpa Medicare Limited | 5.6 Billion INR | 98.097% |
| Valiant Laboratories Limited | 750.89 Million INR | 85.804% |
| Ajanta Pharma Limited | 235.2 Million INR | 54.677% |
| Aarey Drugs & Pharmaceuticals Limited | 32.24 Million INR | -230.607% |
| Granules India Limited | 689.71 Million INR | 84.544% |
| Medicamen Biotech Limited | 12.55 Million INR | -749.064% |
| Ipca Laboratories Limited | 5.8 Billion INR | 98.163% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 8844.873% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.98% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 99.335% |
| NATCO Pharma Limited | 53 Million INR | -101.132% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | 94.191% |
| Strides Pharma Science Limited | 6.71 Billion INR | 98.413% |
| Indoco Remedies Limited | 3.51 Billion INR | 96.969% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Lasa Supergenerics Limited | - INR | -Infinity% |